首批新冠肺炎重症患者今日接受瑞德西韋用藥,可重點關注這4家公司!
格隆匯2月6日丨由美國吉利德公司開發的瑞德西韋2月5日在武漢正式啟動臨牀試驗,第一批病例入組工作就位,首批新型冠狀病毒感染的肺炎重症患者今日接受用藥。
格隆匯綜合梳理了與吉利德有關的上市公司,分別是博騰股份(300363.SZ)、永太科技(002326.SZ)、九洲藥業(603456.SH)以及藥明康德(603259.SH)(2359.HK)。
博騰股份:吉利德為公司核心客户,為吉利德的瑞德西韋提供CDMO服務;
九洲藥業:與吉利德於2011年開始合作,公司已為其提供多個品種的醫藥中間體CDMO 服務,近兩年,吉利德公司的產品銷售收入佔公司營業收入不超過2%;
永太科技:下游客户包括吉利德,在與吉利德接洽在研藥物Remdesivir(瑞德西韋)的中間體採購;
藥明康德:與吉利德自2007年開始合作。2015年、2016年、2017年,吉利德進入了公司銷售的前十大客户之列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.